INTRODUCTION: This open-label pilot study aimed to investigate the efficacy of canakinumab in @entity3812 -resistant @entity827 ( @entity827 ) @entity1 . METHOD: @entity1 with one or more attacks in a month in the preceding 3 months despite @entity3812 were eligible to enter a 30-day run-in period. @entity1 who had an attack during the first run-in period advanced to a second 30-day period. At the first attack, @entity1 started to receive three canakinumab 150 mg subcutaneous injections at 4-week intervals, and were then followed for an additional 2 months. Primary efficacy outcome measure was the proportion of @entity1 with 50 % or more reduction in attack frequency. Secondary outcome measures included time to next attack following last canakinumab dose and changes in quality of life assessed by SF-36. RESULTS: Thirteen @entity1 were enrolled in the run-in period and 9 advanced to the treatment period. All 9 @entity1 achieved a 50 % or more reduction in attack frequency, and only one @entity1 had an attack during the treatment period. C-reactive protein and serum amyloid A protein levels remained low throughout the treatment period. Significant improvement was observed in both physical and mental component scores of the Short Form-36 at Day 8. Five @entity1 had an attack during the 2-month follow-up, occurring median 71 (range, 31 to 78) days after the last dose. Adverse events were similar to those observed in the previous canakinumab trials. CONCLUSION: Canakinumab was effective at controlling the attack recurrence in @entity1 with @entity827 resistant to @entity3812 . Further investigations are warranted to explore canakinumab's potential in the treatment of @entity1 with @entity3812 resistant @entity827 . TRIAL REGISTRATION: ClinicalTrials.gov NCT01088880 . Registered 16 March 2010.

Efficacy and safety of canakinumab in adolescents and adults with XXXX -resistant @entity827 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity827 :: ('MESH:D010505', 'Disease') :: ['familial Mediterranean fever', 'FMF'] @entity3812 :: ('MESH:D003078', 'Chemical') :: ['colchicine']
@entity3812 :: (MESH:D003078,Chemical) :: ['colchicine']
